A Phase II Study of Nimustine Hydrochloride, Cisplatin, and Etoposide Combination Chemotherapy for Supratentorial Malignant Gliomas

Overview

Journal J Neurooncol

Publisher Springer

Date 2001 Feb 24

PMID 11212900

Citations 1

Authors

T Beppu

Y Yoshida

H Arai

T Wada

M Suzuki

A Ogawa

S HAKOZAKI

N Kubo

Affiliations

Soon will be listed here.

Abstract

Twenty-eight patients who were previously treated by aggressive surgery and radiation and were diagnosed with supratentorial malignant gliomas received a combination of nimustine hydrochloride; 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), cisplatin and etoposide (ACE therapy) as primary treatment. Cisplatin and etoposide were given at doses of 20 and 60 mg/m2/day for 5 days, respectively, ACNU doses 80 mg/m2/day on the first day. Treatment was repeated at 4-week intervals for up to 3 cycles. Seventeen patients (60.7%) complained of nausea. Grade 3 or 4 hematological toxicity occurred in 11 patients (39.3%), and grade 3 or 4 renal toxicity occurred in 2 patients. The percentage of patients who showed complete or partial response was 28.6% (8/28). The median time of tumor progression was 40 weeks, and the median survival time was 146 weeks. There were some long-surviving patients who may have benefited from ACE combination. This study demonstrated the effects of ACE combination in patients with supratentorial malignant gliomas.

Citing Articles

A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas.

Beppu T, Kamada K, Nakamura R, Oikawa H, Takeda M, Fukuda T J Neurooncol. 2003; 61(2):161-70.

PMID: 12622455 DOI: 10.1023/a:1022169107872.

References

Yoshida J, Kajita Y, Wakabayashi T, Sugita K . Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien). 1994; 127(1-2):55-9. DOI: 10.1007/BF01808547. View

Tirelli U, DIncalci M, Canetta R, Tumolo S, Franchin G, Veronesi A . Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol. 1984; 2(5):432-7. DOI: 10.1200/JCO.1984.2.5.432. View

Kleihues P, Burger P, Scheithauer B . The new WHO classification of brain tumours. Brain Pathol. 1993; 3(3):255-68. DOI: 10.1111/j.1750-3639.1993.tb00752.x. View

Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M . Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer. 1996; 32A(13):2229-35. DOI: 10.1016/s0959-8049(96)00299-7. View

Ammirati M, Vick N, Liao Y, Ciric I, Mikhael M . Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery. 1987; 21(2):201-6. DOI: 10.1227/00006123-198708000-00012. View

Genka S, Shitara N, Nakamura H, Takakura K . Effect of chemoradiotherapy using ACNU, vincristine, and nicardipine with high-dose irradiation on malignant astrocytomas. Neurol Med Chir (Tokyo). 1993; 33(5):295-9. DOI: 10.2176/nmc.33.295. View

Broggi G, Franzini A . Value of serial stereotactic biopsies and impedance monitoring in the treatment of deep brain tumours. J Neurol Neurosurg Psychiatry. 1981; 44(5):397-401. PMC: 490982. DOI: 10.1136/jnnp.44.5.397. View

Canetta R, Rozencweig M, Carter S . Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985; 12 Suppl A:125-36. DOI: 10.1016/0305-7372(85)90027-1. View

Stewart D, Leavens M, Maor M, Feun L, Luna M, Bonura J . Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res. 1982; 42(6):2474-9. View

10.

Walker M, ALEXANDER Jr E, HUNT W, MacCARTY C, MAHALEY Jr M, Mealey Jr J . Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978; 49(3):333-43. DOI: 10.3171/jns.1978.49.3.0333. View

11.

Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K . Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg. 1986; 64(1):53-7. DOI: 10.3171/jns.1986.64.1.0053. View

12.

Feun L, Wallace S, Stewart D, Chuang V, Yung W, LEAVENS M . Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer. 1984; 54(5):794-9. DOI: 10.1002/1097-0142(19840901)54:5<794::aid-cncr2820540503>3.0.co;2-f. View

13.

Shapiro W, Green S, Burger P, MAHALEY Jr M, Selker R, VanGilder J . Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989; 71(1):1-9. DOI: 10.3171/jns.1989.71.1.0001. View

14.

Drewinko B, Green C, Loo T . Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1976; 60(11):1619-25. View

15.

Boiardi A, Silvani A, Milanesi I, Botturi M, Broggi G . Primary glial tumor patients treated by combining cis-platin and etoposide. J Neurooncol. 1991; 11(2):165-70. DOI: 10.1007/BF02390176. View

16.

Ikeda J, Aida T, Sawamura Y, Abe H, Kaneko S, Kashiwaba T . Phase II study of DTIC, ACNU, and vincristine combination chemotherapy for supratentorial malignant astrocytomas. Neurol Med Chir (Tokyo). 1996; 36(8):555-8; discussion 558-9. DOI: 10.2176/nmc.36.555. View

17.

Matsutani M, Nakamura O, Nakamura M, Nagashima T, Asai A, Fujimaki T . Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults. J Neurooncol. 1994; 19(3):227-37. DOI: 10.1007/BF01053276. View

18.

Ameri A, Poisson M, Chauveinc L, Chen Q, Delattre J . Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. J Neurooncol. 1997; 32(2):155-60. DOI: 10.1023/a:1005784425680. View